The role of tumor markers in non-palpable breast cancers

Screening mammography and clinical breast examination are the best tools available for the diagnosis of breast carcinomas in asymptomatic women. Many studies have attempted to determine the pathological and biological characteristic findings in screening-detected cancers. Tumor size, histologic type, cytological grading and lymph node status have an important role in estimating the biological profile of non-palpable breast cancers. Tissue tumor markers, such as proliferation markers, hormone receptors, c-erbB-2 and p53 oncoproteins, bcl-2 gene and angiogenesis-related markers do not seem to distinguish mammographically detected tumors from clinically presented cancers. Further studies are needed to assess the prognostic role of certain biological factors in well-designed clinical studies along with long follow-up of screened patients.

Non-palpable breast lesions; Breast cancer; Tumor markers

[1] Madigan M., Ziegler R., Benichou C., Byrne C., Hoover R.N.: "Proportion of breast cancer cases in the United States explained by well established risk factors". J. Natl. Cancer Inst., 1995, 87, 1681.

[2] Molina R.:'Tnmor markers in breast cancer". In: Diamandis E., F ritsche H.A., Lilja H., Chan D.W., Schwartz M.K. (eds.). "Tumor Markers. Physiology, Pathobiology, Technology, and Clinical Applications". Washington, DC, AACC Press, 2002, 165.

[3] ACOG.: "ACOG Practice Bulletin. Breast cancer screening. Number 42, April 2003". Int. J. Gynaecol. Obstet., 2003, 81, 313.

[4] Klemi P.J., Joensuu H., Toikkanen S., Tuominen J., Rasanen 0., Tyrkko J. et al.: "Aggressiveness of breast cancers found with and without screening". Br. Med. J., 1992, 304, 467.

[5] Tabar L., Fagerberg G., Day N.E., Duffy S.W., Kitchin R.M.: "Breast cancer treatment and natural history: new insights from results of screening". Lancet, 1992, 339, 412.

[6] Cowan K. W., Kelly P., Sawan A., Cunliffe J. W., Henry L., Higgs J. M. et al.: "The pathological and biological nature of screendetected breast carcinomas: A morphological and immunohistochemical study". J. Pathol., 1997, 182, 29.

[7] Tweedie E., Tonkin K., Kerkvliet N., Doig G.S., Sparrow R.K., O'Malley F.P.: "Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study". Clin. Invest. Med., 1997, 20, 300.

[8] Pagana T.J., Lubbe W.J., Schwartz S.M, Sprechini G.D.: "A comparison of palpable and non-palpable breast cancers". Arch. Surg., 1989, 124, 26.

[9] Isaacs C., Stearns V., Hayes D.F.: "New prognostic factors for breast cancer recurrence". Semin. Oneal., 2001, 28, 53.

[10] Moezzi M., Melamed J., Vamvakas E., lnghirami G., Mitnick J., Quish A. et al.: "Morphological and biological characteristics of mammogram-detected invasive breast cancer". Hum. Pathol., 1996, 27, 944.

[11] Mollino A., Pavarana M., Micciolo R., Nortilli R., Pedersini R., Manno P. et al.: "Comparative study of clinical, pathological and biological characteristics of symptom心c ver、us asymptomatic breast cancers". Ann. Oncol., 2000, 11, 581.

[12] von Rosen A., Frisell J., Glas U., Hellstrom L., Nilsson R., Skoog L., Auer G.: "Non-palpable invasive breast carcinomas from the Stockholm screening project". Acta Oneal., 1989, 28, 23.

[13] von Rosen A., Wiege M., Tornberg B., Hellstrom L., Skoog L., Somell A. et al.: "Relationship between certain radiographic and biologic characteristics in breast cancer". Acta Oncol., 1987, 26, 89.

[14] Ferranti C., Coopmans De Yoldi G., Biganzoli E., Bergonzi S., Mariani L., Scaperrota G. et al.: "Relationships between age, mammographic features and pathological tumour characteristics in non-palpable breast cancer". Br. J. Radiol., 2000, 73, 698.

[15] Karamouzos V. M., Likaki-Karatza E., Barda A. F., Koukouras D., Tsorakoleftherakis E., Papavasiliou G. A. et al.: "Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors". Int. J. Cancer, 2002, 102, 86.

[16] Stark A., Hulka B.S., Joens S., Novotny D, Thor A.D., Wold L.E. et al.: "HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer". J. Clin. Oncol., 2000, 18, 267.

[17] Yamauchi H., Stearns V., Hayes D.F.: "When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer". J. Clin. Oneal., 2001, 19, 2334.

[18] Walker R.A., Dearing S.J., Brown L.A.: "Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast". Hum. Pathol., 1999, 30, 943.

[19] Charpin C., Bonnier P., Khouzami A., Andrac L., Habib M., Yacheret H. et al.: "Nonpalpable breast carcinomas. Histological and immunohistochemical studies of 160 cases". Pathol. Res. Pract., 1993, 189, 267.

[20] Perin T., Canzonieri Y., Massarut S.，Bidoli E., Rossi C., Boncadin M. et al.: "lmmunohistochemical evaluation of multiple biological markers in ductal carcinima in situ of the breast". Eur. J. Cancer, 1996, 32A, 1148.

[21] Bergh J.: "Clinical studies of p53 in treatment and benefit of breast cancer patients". Endocr. Re/at. Cancer. l 999, 6, 51.

[22] Elledge R.M., Green S., Howes L., Clark G.M., Berardo M., Allred D.C. et al.: "Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study". J. Clin. Oncol., 1997, 15, 1916.

[23] Liang Y., Nulander K.D., Yan C., Schor N.F.: "Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by bcl-2" Mol. P harmacol., 2002, 61, 142.

[24] Gasparini G.: "Clinical significance of determination of surrogate markers of angiogenesis in breast cancer". Crit. Rev. Oneal Hematol., 2001, 37, 97.

[25] Stamenkovic I.: "Matrix matalloproteinases in tumor invasion and metastasis". Semin. Cancer Biol., 2000, 10, 415.